| Not Yet Recruiting | Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC NCT07353476 | Shanghai Zhongshan Hospital | Phase 2 |
| Not Yet Recruiting | Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metast NCT07343479 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure NCT07528274 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients W NCT07469488 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 4 |
| Not Yet Recruiting | ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC NCT07524257 | ImmunityBio, Inc. | Phase 3 |
| Not Yet Recruiting | Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC NCT07158489 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965 | Guangzhou University of Traditional Chinese Medicine | N/A |
| Recruiting | A Retrospective Real-World Study Based on RATIONALE-307 NCT07478809 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Not Yet Recruiting | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally NCT07418866 | Fudan University | Phase 2 |
| Not Yet Recruiting | Anlotinib in Cross-line Treatment of NSCLC and SCLC NCT07400575 | Henan Cancer Hospital | — |
| Recruiting | A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary An NCT07361237 | Tongji University | Phase 1 |
| Recruiting | Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cance NCT06992739 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663 | Beijing Tide Pharmaceutical Co., Ltd | Phase 1 / Phase 2 |
| Recruiting | Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Pat NCT07001618 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Recruiting | QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC NCT07330596 | Anhui Provincial Cancer Hospital | Phase 2 |
| Active Not Recruiting | Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer NCT07262671 | Fudan University | — |
| Recruiting | A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Not Yet Recruiting | Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer NCT06951399 | Rabin Medical Center | Phase 2 |
| Not Yet Recruiting | Immune-Marker Platform for Patients With Advanced Lung Cancer NCT07150598 | Technische Universität Dresden | — |
| Recruiting | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors NCT07085091 | ALX Oncology Inc. | Phase 1 |
| Recruiting | Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management NCT07356544 | Gruppo Oncologico Italiano di Ricerca Clinica | — |
| Recruiting | A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutat NCT06946927 | Jemincare | Phase 1 |
| Not Yet Recruiting | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After NCT07014215 | Anhui Provincial Cancer Hospital | Phase 2 |
| Recruiting | A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line NCT06969612 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 | Revolution Medicines, Inc. | Phase 3 |
| Not Yet Recruiting | Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function NCT06823258 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation NCT06775743 | Fudan University | Phase 2 |
| Recruiting | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations NCT06706076 | BlossomHill Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors NCT06652529 | Aromics Therapeutics | Phase 1 |
| Recruiting | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861 NCT06956001 | Allist Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer NCT06653023 | Wondercel Biotech (ShenZhen) | EARLY_Phase 1 |
| Recruiting | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer NCT06604689 | Fudan University | — |
| Recruiting | Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer NCT07259447 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Recruiting | EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients NCT07096258 | Hedera Dx SA | — |
| Recruiting | Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-c NCT07288632 | University Of Perugia | — |
| Recruiting | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung NCT06896890 | Inhatarget Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 | Sairopa B.V. | Phase 1 |
| Active Not Recruiting | Prognostic Correlation Between the Ratio of the Neutrophil Ratio to the Ratio of CD4+/CD8+ T Cells in Patients NCT06954259 | Qiang Xu | — |
| Completed | A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer NCT07121387 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Active Not Recruiting | Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases NCT07491211 | Fudan University | — |
| Completed | Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC NCT06613633 | Fudan University | — |
| Completed | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lun NCT01211483 | Daiichi Sankyo | Phase 1 / Phase 2 |